NeoStem is a leader in the emerging cellular therapy industry. The company’s business model involves the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing business that provides services to others in the regenerative medicine industry.

The company announced today the extension of intellectual property protection around its lead product candidate, AMR-001, with the notice of a patent allowance in Canada. The Canadian patent protects a chemotactic stem cell product enriched for CD34+ cells that treat injury from acute myocardial infarction. Like most countries, cardiovascular disease is a significant problem in Canada too. Heart disease accounts for over 20% of deaths in Canada.

NeoStem’s AMR-001 is a cell therapy in development for treatment of cardiovascular disease. The company is on target to complete enrollment in 2013 in the Phase 2 PreSERVE AMR-001 double-blind clinical trial. The goal of the trial is to investigate the safety and efficacy of AMR-001 in preserving heart function after a heart attack in a particular type of post-heart attack patient. NeoStem is expected to have the first data read-out available six to eight months after the last patient is enrolled.

The granting of the patent by Canada brings the total global patent coverage to ten countries. If the company’s trials warrant approval by the FDA, it would position NeoStem to capture a meaningful share of the worldwide acute myocardial infarction market.

For additional information about NeoStem and its lead product candidate, AMR-001, please visit www.neostem.com

Let us hear your thoughts below: